Protocols, Equipment for New Medical iPhone App

Emerging Healthcare Solutions, Inc.'s board members met with medical experts to discuss protocols for the new app being developed by the company for use with medical devices for at home diagnosis and monitoring of various blood disorders. Among those being discussed was an app module to be used with a device for home monitoring Prothrombin Time (PT)/INR, a critical test performed to maintain the proper therapeutic range of oral anticoagulation therapies for patients taking such blood thinning drugs as Coumadin and Warfarin. Patients with mechanical heart valves and those suffering from atrial fibrillation are among the many that could benefit from self-testing at home.

More than 7 million people worldwide take oral anticoagulants to help reduce the body's chances of forming harmful blood clots. Just as self-testing of blood glucose has revolutionized the management of diabetes, self-testing for Prothrombin Time has the potential to provide a positive impact on patient therapeutic outcomes as well as resulting in fewer trips to labs and clinics for patients.

EHSI took the lead in the new mobile Telemedicine industry through their prior licensing and development of an extraordinary ambulance trauma communications platform. This system was originally the brainchild of Dr. Red Duke and was funded through a $20 million US Department of Defense grant to the University of Texas Health Sciences Center at Houston. UT then engaged Texas A&M to fully develop the system.

iPhone is a portable data device produced by Apple, Inc. It allows users to download and operate 'applications' that empower the portable device to deliver a wide variety of additional services. The iPhone competes with Google, Inc. Android system and with Research-in-Motion's Blackberry phones. The emerging medical technology sector also includes Gilead Sciences.